Buzz around Campath proof-of-concept trial in MS

Whether Campath (alemtuzumab), a monoclonal antibody (mAb) already approved to treat leukemia, actually reverses MS, as some news stories in the mainstream media have trumpeted, and how it works, remain unresolved. The next two years are expected to reveal much about not only Campath in MS, but also...

Full description

Saved in:
Bibliographic Details
Published in:Nature biotechnology 2009-01, Vol.27 (1), p.6-8
Main Author: Osborne, Randy
Format: Article
Language:English
Subjects:
Agriculture
Alemtuzumab
Animals
Antibodies, Monoclonal - therapeutic use
Antibodies, Monoclonal, Humanized
Antibodies, Neoplasm - therapeutic use
Antineoplastic Agents - therapeutic use
Bioinformatics
Biomedical and Life Sciences
Biomedical Engineering/Biotechnology
Biomedicine
Biotechnology
Brain - drug effects
Cancer
Clinical Trials as Topic
Complications and side effects
Drug therapy
Effectiveness
Humans
Immunotherapy - methods
Leukemia
Life Sciences
Magnetic Resonance Imaging - methods
Multiple sclerosis
Multiple Sclerosis - drug therapy
news
Patient safety
Pharmacology
Rats
Treatment Outcome
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Whether Campath (alemtuzumab), a monoclonal antibody (mAb) already approved to treat leukemia, actually reverses MS, as some news stories in the mainstream media have trumpeted, and how it works, remain unresolved. The next two years are expected to reveal much about not only Campath in MS, but also the competitive landscape for this indication where the tradeoff between efficacy and safety remains a tough hurdle for drug developers.
ISSN:1087-0156
1546-1696
DOI:10.1038/nbt0109-6